KM Research Hub
← 返回论文库
待处理 入排:待复核 图源:待检查 入排置信度 0.00

Effects of SMOFlipid-based versus soybean oil-based high-protein parenteral nutrition on hematologic, biochemical, and clinical outcomes after allogeneic hematopoietic stem cell transplantation in children with acute leukemia: a randomized double-blind controlled trial.

Melika Hajimohammadebrahim-Ketabforoush, Amir Ali Hamidieh, Maryam Behfar, Zahra Vahdat Shariatpanahi

Nutrition 154 113453

PMID43057068
PMCID-
DOI10.1016/j.nut.2026.113453
发表日期2026-11-19
入排依据:未在 PubMed 元数据中确认 Phase III/IIIb 或 Phase II/III 证据,需复核正式试验阶段。
摘要

摘要

BACKGROUND: Optimal parenteral nutrition (PN) strategies, especially the parenteral lipid composition, for children undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT) remain uncertain. METHODS: We conducted a randomized double-blind trial comparing high-protein PN containing SMOFlipid with soybean oil-based PN (Intralipid) in pediatric patients undergoing allo-HSCT for acute leukemia. Forty-six participants completed the study (SMOFlipid, n = 22; Intralipid, n =24). Primary outcomes were neutrophil and platelet engraftment; secondary outcomes included anthropometric, biochemical, inflammatory, and clinical parameters. RESULTS: Neutrophil engraftment was similar between groups, whereas platelet engraftment occurred later in the SMOFlipid group. Both groups experienced nutritional deterioration during the early post-transplant period; however, SMOFlipid was associated with better preservation of anthropometric measures and more favorable metabolic trajectories, including lower triglyceride excursion and improved glycemic patterns. Adjusted interleukin-6 concentrations were higher in the SMOFlipid group. Although infection rates were similar, adjusted analyses suggested lower hazards of acute graft-versus-host disease and 100-day mortality with SMOFlipid. Kaplan-Meier analysis also demonstrated improved in-hospital survival. CONCLUSION: SMOFlipid-based PN was associated with favorable metabolic and body-composition outcomes during early recovery after pediatric allo-HSCT, although platelet engraftment was modestly delayed and inflammatory markers were higher. Larger multicenter studies are required to confirm these findings. TRIAL REGISTRATION: ClinicalTrials.gov: NCT06625372.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。